



Current as of November 15, 2024

Poster Session A (To be presented on November 17 from 7:30-9:00 p.m. ET)

A001 Reciprocal activation of breast cancer metastases and the lung epithelium during metastatic outgrowth. Jessica Christenson. University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States.

A002 Dissecting the Brain Metastatic Microenvironment to Uncover Immune and Molecular Correlates of Response to Immunotherapy. Amelie Daugherty-Lopes. National Cancer Institute, NCI_ National Institutes of Health, NIH, Bethesda, Maryland, United States.

[WITHDRAWN] A003 The role of aging in promoting immune mediated reactivation from metastatic melanoma dormancy. Mitchell Fane. Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States.

A004 E2F5 conditional knockout in mammary epithelium drives organotropic metastasis in breast cancer. Jesus Garcia Lerena. Michigan State University, East Lansing, Michigan, United States.

A005 Patient-derived cancer associated fibroblasts induce varying rates of colorectal cancer cell invasion using an organ-on-chip model. Bethany Haliday. University of Southern California, Los Angeles, California, United States.

A006 Investigating the effects of fibroblasts derived from the primary versus the metastatic organ on 3D biomimetic models of pancreatic cancer. Mahsa Pahlavanneshan. Ellison Institute of Technology, Los Angeles, California, United States.


A007 Emergence of metastasis-initiating cells during lung adenocarcinoma progression. Jin Suk Park. MSKCC, New York, New York, United States.

A008 Microenvironmentally released cytokines mediate organ specific transcriptional profiles for metastatic colorectal cancer. Jonathan Rennhack. Loyola University Chicago, Maywood, Illinois, United States.

A009 PIEZO1 driven tumor aggressiveness in an organ-on-chip model of colorectal cancer. Curran Shah. University of Southern California, Los Angeles, California, United States.

A010 Development and characterization of novel models of lobular breast cancer metastases. Joseph Sottnik. University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®

2403001E

A011 Assessing pro-tumorigenicity of the aging microenvironment in a murine ovarian cancer model. Katherine Cummins. University of Pennsylvania, Philadelphia, Pennsylvania, United States.

A012 Aging drives TNBC lung metastasis dependency on FGFR-triggered metabolic reprogramming exposing an age-induced liability with therapeutic potential. Stanislav Drapela. H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States.

A013 Microenvironment driven dynamic deposition of histone H3.3 controls entry and exit from dormancy in disseminated cancer cells. Stanislav Drapela. H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States.

A014 Effects of senescence on the lung tumor microenvironment. Luis Prieto. Mayo Clinic, Rochester, Minnesota, United States.

A015 Aging limits stemness and tumor development in the lung by reprogramming iron homeostasis. Xueqian Zhuang. Memorial Sloan Kettering Cancer Center, New York, New York, United States.

A016 Targeting metabolic vulnerability of non-small cell lung cancer with annonacin and 2-deoxy-d-glucose in individual and combination modality. Bhoj Raj Bhattarai. Kentucky State University, Frankfort, Kentucky, United States.

A017 HER2 overexpression initiates breast tumorigenesis non-cell-autonomously by altering energy metabolism in the tissue microenvironment. Sevim Gurler. University of Manchester, Manchester, United Kingdom.


A018 Endothelial pyrimidine synthesis deficiency promotes tumor growth. Petra Hyrossova. Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czech Republic.

A019 Increased Vulnerability of Colorectal Cancer with High Alkylation Damage to NTHL1 Inactivation. Hyeoncheol Kim. Dana Farber Cancer Institute, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States.

A020 Elevated Extracellular Glucose Level in Tumor Microenvironment by Hyperglycemia Increases Glycolysis Rate, Stiffness, Contractility, and Motility of Breast Cancer Cells through the cAMP-RhoA-Rock and AMPK-YAP-RhoA Axes to Promote Metastasis. Tae-Hyung Kim. University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States.

A021 HRI inhibition by hemin as a novel targeted therapy for glioblastoma via the integrated stress response. Xingchuan Ma. Portsmouth Abbey School, Portsmouth, Rhode Island, United States.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and
Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®

2403001E

A022 Disrupting redox homeostasis initiates anti-tumour immune responses in pancreatic cancer. Lucie Malbeteau. Princess Margaret Cancer Center, Toronto, Ontario, Canada.

A023 Arachidonic acid metabolism promoting cross resistance in melanoma cells. Casey Stefanski. Thomas Jefferson University, Philadelphia, Pennsylvania, United States.

A024 Tissue Biomarkers in the Tumor Microenvironment Predicting the Development of Cachexia in Pancreatic Cancer Patients. Moon Jae CHUNG. Yonsei University College of Medicine, Seoul, South Korea.

A025 Extracellular-vesicles from the peri-prostatic adipose tissue of obese, but not lean, men promote prostate cancer aggressivity. Nil Grunberg. Imperial College London, London, United Kingdom.

A026 Assessing the Impact of Obesity on Postoperative Outcomes in RCC Using Machine Learning. Atulya Khosla. Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, United States.

A027 Acceleration of drug metabolism mediated by CYP3A4 enzyme activation provides a bona fide environmental resistance mechanism to targeted therapies. Pragma Kumar. Moffitt Cancer Center, Tampa, Florida, United States.

A028 Direct interaction between cancer cells and fibroblasts drives epithelial- to-mesenchymal plasticity (EMP) and chemotherapy resistance. Nilu Dhungel. LSU Health Science Center, Shreveport, Louisiana, United States.

A029 Integrated modeling of renal cancer bone metastasis to illuminate tumor progression and therapy response. Eleonora Dondossola. UT MD Anderson Cancer Center, Houston, Texas, United States.


A030 Polycomb repressive complex 2 (PRC2) mediates the epigenetic regulation of cancer-associated fibroblasts in esophageal cancer. Karen Dunbar. Columbia University, New York, New York, United States.

A031 ECM architecture drives distinct evolutionary patterns of tumor immune escape and elimination in breast cancer. Yijia Fan. Texas A&M University, Houston, Texas, United States.

A032 Uncovering the impact of current therapies on LUAD dormant metastasis. Inês Godet. Memorial Sloan Kettering Cancer Center, NEW YORK, New York, United States.

A033 Integrating spatial transcriptomics and second harmonic generation imaging to identify targets of supermere-associated Discoidin Domain Receptor 1 involved in collagen alignment. Maxwell Hamilton. Vanderbilt University, Nashville, Tennessee, United States.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®

2403001E

A034 Single cell RNA sequencing of triple negative breast cancer patient-derived xenograft model identifies CRABP1 of cancer-associated fibroblast as a key regulator of breast cancer metastasis. Woohang Heo. Biomedical Research Institute, Seoul National University Hospital, Seoul, Seoul, South Korea.

A035 Infection of primary mammary fibroblasts with cytomegalovirus coordinately increases autotaxin-lysophosphatidate-inflammatory signaling, which could increase breast cancer metastasis. Humayara Khan. University of Alberta, Edmonton, Alberta, Canada.

A036 DDR2 in ovarian tumor CAFs controls ferroptosis and response to Olaparib. Julien Lesage. Washington University in St. Louis, St. Louis, Missouri, United States.

A037 The impact of cell-matrix interactions on the chemoresponse of breast cancer cells. Elizabeth Moore. Cornell University, Ithaca, New York, United States.

A038 A targetable tumor-induced wound-healing response is essential for osteosarcoma lung metastasis. Ryan Roberts. Nationwide Children's Hospital/The Ohio State University, Columbus, Ohio, United States.

A039 Characterization of the heterogeneous nature of the peritumoral zone of glioblastomas and its relevance for the clinical progression of the disease. Pilar Sánchez-Gómez. Instituto de Salud Carlos III, Madrid, Spain.

A040 A novel stroma-mediated positive interaction between resistant and sensitive cells in non-small cell lung cancer facilitates drug resistance. Rishi Shah. Moffitt Cancer Center & Research Institute, Tampa, Florida, United States.


A041 Deciphering the crosstalk between cancer cells and stroma that drives EMT- coupled fibrosis. Elena Spina. Memorial Sloan Kettering Cancer Center, New York, New York, United States.

A042 Desmosome mutations in the microenvironment regulate melanoma proliferation. Mohita Tagore. Memorial Sloan Kettering Cancer Center, New York, New York, United States.

A043 Senescent CAFs modulate tumor immunity and promote breast cancer progression. Jiayu Ye. Washington University in St. Louis, St. Louis, Missouri, United States.

C026 Discovery characterization of small molecules to enhance Natural Killer cell cytotoxicity against solid tumors. Indrani Das. Case Western Reserve University School of Medicine, Cleveland, Ohio, United States.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and
Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®

2403001E

Poster Session B (To be presented on November 18 from 7:30-9 p.m. ET)

B001 Intra- and Inter-Tumoral Heterogeneity of Melanoma Across Different Metastatic Sites. Veronica Aedo Lopez. Research Division Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

B002 Dynamic response and evolving adaptation of pancreatic cancer cells to the prolonged acidic pH microenvironment. Wun-Shaing Wayne Chang. National Health Research Institutes, Zhunan, Taiwan.

B003 In vitro 3D bone marrow niches for AML cells. Barbara Pui Chan. The Chinese University of Hong Kong, Hong Kong.

B004 Identification of distinct subpopulations of cancer associated fibroblasts in oral squamous cell carcinoma by imaging mass cytometry. Daniela Elena Costea. University of Bergen and Haukeland University Hospital, Bergen, Norway.

B005 Exploring breast cancer heterogeneity in the context of metastatic tumour microenvironments and therapy resistance. Sreeja Gadipally. Olivia Newton John Cancer Research Institute, Heidelberg, Canada.

B006 Role of the BAF Complex in Pancreatic Cancer-Associated Fibroblast Function. Jaye Gardiner. Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States.

B007 Identification of Asporin as a HER3 ligand exposes a therapeutic vulnerability in metastatic prostate cancer. Amanda Hesterberg. Vanderbilt University, Nashville, Tennessee, United States.

B008 Therapy-protective peritumoral niches mediate positive ecological interaction between therapy-sensitive and therapy-resistant cells, altering the evolutionary dynamics of acquired targeted therapy resistance in lung cancers. Andriy Marusyk. Moffitt Cancer Center, Tampa, Florida, United States.

B009 Characterization and CRISPR perturbation of cancer-associated fibroblast heterogeneity in in vitro models. Elysia Saputra. Merck & Co., Inc., Rahway, New Jersey, United States.

B010 Improving Pancreatic Cancer Image Classification with Transfer Learning: CD45 vs. PANCK. Miracle Thomas. University of District of Columbia, Washington, DC, United States.

B011 Sensory neurons regulate intracellular and intercellular mitochondrial dynamics in breast cancer cells. Ankit Tiwari. Cold Spring Harbor Laboratory, New York, New York, United States.

B012 Understanding the role of VISTA in regulating T cell function and the therapeutic potential of blocking VISTA in Triple Negative Breast Cancer. Maidinimu Abudula. University of Liverpool, Liverpool, United Kingdom.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and
Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



B013 Hallmarks of progression in early neoantigen-expressing lung adenocarcinoma. Ishan Bansal. Yale University, New Haven, Connecticut, United States.

B014 NRF2 regulation of the immune microenvironment in breast cancer. Yasemin Ceyhan Ozdemir. Fred Hutch Cancer Center, Seattle, Washington, United States.

B015 Targeting CX3CL1 transforms a cold tumor microenvironment into a hot one by enhancing T cells and DCs locally and systemically. Piyush Chaudhary. Huntsman Cancer Institute, Salt Lake City, Utah, United States.

B016 Utilizing gene expression profiles (GEP) to assess tumor microenvironment (TME) and response to immunotherapy. Changde Cheng. University of Alabama, Birmingham, Birmingham, Alabama, United States.

B017 The double-edged sword of cystatin B in luminal-like and triple-negative breast cancers. Claudia Chiodoni. Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

B018 Multifaceted pro-metastatic role of IL-17 signaling in modulating the tumor microenvironment of colorectal cancer. Katarzyna Chojnacka. Cedars Sinai, Los Angeles, California, United States.


B019 Regulatory macrophages contribute to tumor cell plasticity in colorectal cancer metastases. Matthew Cottam. Vanderbilt University Medical Center, Nashville, Tennessee, United States.

B020 Lean adipocyte-secreted oxylipin, 9S-HODE, triggers ferroptosis and protects against obesity-accelerated breast cancer. Meghan Curtin. University of Utah, Salt Lake City, Utah, United States.

B021 Aneuploidy-associated cohesin RAD21 gains promote immune evasion in prostate cancers. Elise DeArment. Center for Prostate Disease Research, Murtha Cancer Center Research Program, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States.

B022 Investigating how monocytes impair NK cell cytotoxicity in lung metastasis of triple-negative breast cancer. Christos Ermogenous. Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

B023 Regulatory T (Treg) cell contributes to tumor cell dissemination via extracellular matrix (ECM) remodeling, which is driven by TAMs in an IFN γ -dependent manner. Ailen Garcia-Santillan. Virginia Commonwealth University, Richmond, Virginia, United States.



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research*

2403001E

B024 Deciphering the neurogenic tumor microenvironment: A novel gene network driving innervation in metastatic melanoma offers prognostic and therapeutic insights. Anjana Goli. Stanford Online High School, St. Louis, Missouri, United States.

B025 Primary and metastatic tumors from triple negative breast cancer possess distinct immunological profiles. Alexandra Goudreau. McGill University, Montreal, QC, Canada.

B026 Pancreatic tumor extracellular vesicles induce perineural invasion in vitro via IL-8/CCL2. Emory Gregory. University of Arkansas, Fayetteville, Arkansas, United States.

B027 ISG15 modulate cancer cell mechanics and metastasis in breast cancer. Mohamed Haloul. University of Illinois at Chicago, Chicago, Illinois, United States.

B028 The Role of cDC1 Gene Signatures in Gastric Cancer Prognosis and Immune Microenvironment Modulation. song-hee han. Dong-A University College of Medicine, Busan, South Korea.

B029 Mapping the vascular walls of colorectal cancer. Linglong(凌龙) Huang(黄). Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden.

B030 Productive T-cell-mediated immunoediting of developing sarcomas by distinct mechanisms. Brian Hunt. Yale School of Medicine, New Haven, Connecticut, United States.

B031 Lean adipocyte-derived lipid decreases metastatic potential of breast cancer cells. Abigail Jackson. University of Utah, Salt Lake City, Utah, United States.


B032 Spatial study of Tertiary Lymphoid Structures in Lung Adenocarcinoma using 3D Lightsheet whole-organ Imaging and machine learning-based quantification. Advait Jeevanandam. Yale University, New Haven, Connecticut, United States.

B033 Identification of cell-specific DNA methylation alterations in the breast tumor microenvironment. Barbara Karakyriakou. Dartmouth Geisel School of Medicine, Hanover, New Hampshire, United States.

B034 Engineering the tumor microenvironment: Patient-specific microphysiological systems of the head and neck cancer tumor microenvironment. Sheena Kerr. University of Wisconsin, Madison, Madison, Wisconsin, United States.

B035 Reciprocal macrophage - T cell interactions regulate anti-tumor immunity. Kelly Kersten. Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®

2403001E

B036 WEE1 confers resistance to PD-1 blockade via hyperactivation of the AKT signaling pathway. Hyo-Jung Lee. Korea University, Seoul, South Korea.

B037 Expression of MRTFA facilitates an immunosuppressive tumor microenvironment via upregulation of VSIR. Kihak Lee. University of Illinois Chicago - College of Medicine, Chicago, Illinois, United States.

B038 Establishing a screening platform to identify key signaling molecules regulating cold tumor formation through immune evasion and exclusion. Wen-Jye Lin. National Health Research Institutes, Miaoli county, Taiwan.

B039 Exploring the impact of neoantigen expression on lung tumor development. Jennifer Loza. Yale University, New Haven, Connecticut, United States.

B040 Investigating the impact of tumor EMT states on immune cell infiltration in breast cancer. Hanxu Lu. Dartmouth College, Hanover, New Hampshire, United States.

B041 Investigating the impact of extracellular matrix stiffness on macrophage function and organoid growth in Pancreatic ductal adenocarcinoma. Bayan Mahgoub. University of Southern California, Los Angeles, California, United States.

B042 The impact of opioids on the pancreatic tumor immune microenvironment. Kathryn Maraszek. Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.

B043 BDNF-TrkB.T1 signaling increases neutrophil recruitment and epithelial-to-mesenchymal transition in gliomas. Leyre Merino-Galan. Seattle Children's Research Institute, Seattle, Washington, United States.


B044 Spatial transcriptomics reveals a distinct B cell signature in the dormant prostate cancer bone microenvironment. Mostafa Nasr. H. Lee Moffitt Cancer Center, Tampa, Florida, United States.

B045 Requirement of Mena INV for metastatic colonization of the lungs by breast cancer stem cells. Mohd Nauman. Albert Einstein College of Medicine, Bronx, New York, United States.

B046 Pyk2 and MEK/ERK signaling regulate the extracellular vesicle release and tumor-associated myeloid Cells in glioblastoma. Neisha Ramirez. Universidad Central del Caribe, Puerto Rico.

B047 Understanding the role of cancer-associated adipocytes in breast tumor microenvironment to delineate the relationship between obesity and cancer. Yaechan Song. Yonsei University, South Korea.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and
Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®

2403001E

B048 Neutrophil extracellular traps-targeting DNase I enhances the therapeutic efficacy of CAR-T cell adoptive immunotherapy in a syngeneic murine metastasis model. Alexey Stepanov. Scripps Research, ON, Canada.

Poster Session C (To be presented on November 19 from 5-6:30 p.m. ET)

C001 P21-positive senescent stromal cells promote prostate cancer immune suppression and progression that can be reversed by senolytic therapy. Marcus Ruscetti. University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States.

C002 MPLA+IFN γ -activated tumor-associated macrophages alter fibroblast composition. Lijuan Sun. Johns Hopkins University, Baltimore, Maryland, United States.

C003 Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling. Whitney Tamaki. University of California, San Francisco, San Francisco, California, United States.

C004 TGF- β induces an atypical EMT to evade immune mechanosurveillance in lung adenocarcinoma dormant metastasis. Zhenghan Wang. Memorial Sloan Kettering Cancer Center, New York, New York, United States.

C005 The role of Liver Receptor Homolog 1 (LRH-1) in regulating cancer progression by modulating the immune response. Yu Wang. University of Illinois Urbana-Champaign, Urbana, Illinois, United States.


C006 Decreased heterogeneity in immune interactions in oral cavity squamous cell carcinoma patients with recurrence. Connie Zhou. University of California, San Francisco, San Francisco, California, United States.

C007 Glucocorticoids establish a metastatic-promoting tumor microenvironment in a PDAC mouse model. Xiao Han. Johns Hopkins University School of Medicine, Baltimore, Maryland, United States.

C008 Degradation of extracellular trap DNA sustains anti-tumor immune responses in breast cancer. Sabina Sangaletti. Fondazione IRCCS Istituto Nazionale dei Tumori, Cambridge, Massachusetts, United States.

C009 Dissemination of retrotransposable elements from the non-coding genome in tumor-derived extracellular vesicles target stromal and immune cells to induce local and systemic

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and
Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®
2403001E

inflammation. Laszlo Radvanyi. Ontario Institute for Cancer Research, Toronto, Massachusetts, United States.

C010 Tumor-associated macrophages drive prostate cancer progression via IL-1 β signaling. Young Sun Lee. Memorial Sloan Kettering Cancer Center, New York, Kansas, United States.

C011 IL-27R signaling modulates protective versus pathogenic T cell responses in hepatocellular carcinoma. Zhengzheng Shi. Cedars-Sinai Medical Center, Los Angeles, California, United States.

C012 Identifying the role of Interleukin-17 signaling in intestinal stem cells during pancreatic cancer. Haoyue Liu. The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

C013 CKLF attracts CCR4-expressing CD4+ cells to foster immune repression and tumor aggressiveness in MYCN-driven neuroblastoma. Hui Feng. Boston university, Boston, Massachusetts, United States.

C014 IL27R signaling regulates neutrophils maturation, activation and function in colorectal cancer-liver metastases. Jiani Zhu. Cedars-Sinai Medical Center, Los Angeles, California, United States.

C015 Awakened dormant cancer cells undergo highly mesenchymal to quasi-mesenchymal transition and acquire stemness. Jingwei Zhang. Whitehead institute for biomedical research, Cambridge, Massachusetts, United States.

C016 Outer membrane vesicles from Bacteroides fragilis contain coding and non-coding small RNA species that modulate inflammatory signaling in intestinal epithelial cells. K. Greathouse. Baylor University, Waco, Texas, United States.

C017 Tumor MK2 drives tumor progression and an immunosuppressive microenvironment in head and neck squamous cell carcinoma. Dakota Okwuone. University of Kansas Medical Center, Kansas City, Kansas, United States.


C018 Age dictates immune response within the tumor microenvironment of triple negative breast cancer. Milos Spasic. Brigham and Women's Hospital, Boston, Massachusetts, United States.

C019 New insights from a novel mouse model of Synovial Sarcoma. Hesham Mohei. University Of Pennsylvania, Philadelphia, Pennsylvania, United States.

C020 Single cell analysis reveals tumor size-driven immune changes in primary breast tumors and corresponding lymph nodes. Inga Hansine Rye. Dep.of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

C021 Exploring the composition of and interaction of the tumor microenvironment in Langerhans cell histiocytosis. Wouter van Midden. St. Anna Children's Cancer Research Institute, Vienna, Austria.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research*

2403001E

C022 The impact of reproductive factors on breast tumor and normal-adjacent tissue immune profile from menarche to menopause. Cheng Peng. Brigham and Women's Hospital, Boston, Pennsylvania, United States.

C023 MK2 knockout and radiation enhances immune cell influx in a mouse model of HPV+ head and neck squamous cell carcinoma. Deri Morgan. KUMC, Kansas City, Kansas, United States.

C024 Tumor vaccines and oncolytic virotherapy: systemic immunity vs. tumor microenvironment. WILLIAM JIA. Virogin Biotech Ltd, Vancouver, Canada.

C025 Cytomegalovirus infection modulates distinct immune cell dynamics across tumor-immune microenvironments and systemic macroenvironment during metastasis. Wenjuan Dong. Houston Methodist Research Institute, ADELAIDE, Texas, United States.

C027 Tumor-associated microbiota suppresses anti-tumor immunity by driving cDC1 dysfunction in lung cancer. Chengcheng Jin. University of Pennsylvania, Philadelphia, Pennsylvania, United States.

C028 Exercise reduces pancreatic tumor in a gut microbiome dependent manner. Sumedha Pareek. University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

C029 PM2.5-Induced Drug Resistance in Lung Cancer. Chi-Yuan Chen. Chang Gung University of Science and Technology, Taoyuan, Taiwan.


C030 Timing of melanoma brain metastasis seeding dictates the immunomodulatory effect and efficacy of systemic anti-CD40 agonist therapy. Vinton Cheng. University of Birmingham, Birmingham, United Kingdom.

C031 Targeting colorectal cancer-associated fibroblasts with all-trans retinoic acid to reprogram the tumor microenvironment. Brandon Choi. Ellison Institute of Technology, Los Angeles, California, United States.

C032 The impact of neoadjuvant endocrine therapy (NET) in ER+ breast cancer tumor microenvironment and metastasis. Anastasia Aristoteleia Chondronikola. Albert Einstein College of Medicine, Bronx, New York, United States.

C033 Identifying and targeting prostate cancer therapy resistance mechanisms driven by the tumor microenvironment. Tony Lok Heng Chu. Fred Hutchinson Cancer Center, Seattle, Washington, United States.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and
Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research®

2403001E

C034 Investigating residual disease in its spatial context in BRCA1;p53-deficient mammary tumors. Morgane Decollogny. Institute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.

C035 Spatially limited stroma-mediated resistance potentiates targeted therapy resistance through an integration of multiple juxtacrine and paracrine mechanisms. Bina Desai. H. Lee Moffitt Cancer Center, Tampa, Florida, United States.

C036 Pharmacological modulation of glutamine metabolism alters macrophage activity and tumor immune responses. Jiawei Fan. Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States.

C037 Chemotherapy causes de novo induction of invasive breast cancer cells. Madeline Friedman-DeLuca. Albert Einstein College of Medicine, Bronx, New York, United States.

C038 Harnessing NK cells to improve targeted therapy therapeutic efficacy in BRAF-mutant melanoma. Chia-Hsin Hsu. Cornell University, Ithaca, New York, United States.

C039 The impact of antiangiogenic therapy on blood vessels and CD8 infiltration in renal cancer metastases is space, time, site, dose, and drug dependent. Stefan Maksimovic. MD Anderson Cancer Center, Houston, Texas, United States.

C040 Spatial transcriptomics unveils disparities in tumor microenvironment dynamics between breast cancer responders and non-responders. Jeremy Mo. Garvan Institute of Medical Research, Darlinghurst, NSW, United States.


[WITHDRAWN] C041 MYC and p53 alterations cooperate through VEGF signaling to repress cytotoxic T cell and immunotherapy responses in prostate cancer. Katherine Murphy. UMass Chan Medical School, Worcester, Massachusetts, United States.

C042 TMEM doorway score as a predictive biomarker for therapy selection in ER+/HER2- breast cancer. Priyanka Parmar. Montefiore/Einstein, Bronx, New York, United States.

C043 Alprazolam abrogates the secretion of proinflammatory cytokines in PDAC CAFs. Hunter Reavis. Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States.

C044 Single cell RNA-sequencing coupled with lineage tracing identifies novel clonal populations associated with immunotherapy resistance. Reem Saleh. Peter MacCallum Cancer Centre, Melbourne, VIC, Canada.

American Association for Cancer Research® Special Conference in Cancer Research
AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in Cancer
In association with the AACR Tumor Microenvironment (TME) Working Group
November 17-20, 2024, | Boston, MA



AACR Special Conference on
**Tumor-body Interactions:
The Roles of Micro- and
Macroenvironment in Cancer**
Nov. 17-20, 2024 | Boston, MA

REGISTER
TODAY!

AACR
American Association
for Cancer Research*

2403001E

C045 The extracellular matrix glycoprotein periostin supports chemotherapy resistance by modulating macrophage recruitment and phagocytosis in triple negative breast cancer. Ludovica Tarantola. Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

C046 PARP inhibitors as immune modulators in metastatic ovarian cancer treatment. Sarka Vosahlikova. 1Sotio Biotech, Prague, Czech Republic.

C047 AGX101: Preclinical evaluation of a TM4SF1-directed tubulin inhibitor conjugate with ongoing first-in-human trial. Glen Weiss. Angiex, Boston, Massachusetts, United States.

C048 Inpatient heterogeneity and targeting microenvironment protection mechanisms in melanoma metastasis. Haley Wilson. Thomas Jefferson University, Philadelphia, Pennsylvania, United States.

C049 Implementing human bone marrow organoids to interrogate microenvironmental influences on the efficacy of blood cancer immunotherapies. Zoë Wong. University of Oxford, Oxford, United Kingdom.

C050 Leveraging ECM deposition by CAF-like Ewing sarcoma tumor cells to target micrometastases with matrix-binding VHHs. Emma Wrenn. Seattle Children's Research Institute, Seattle, Washington, United States.

C051 Epigenetic reprogramming of brain-infiltrating myeloid cells deters brain metastasis outgrowth. Shao-Ping Yang. The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

C052 Induction of senescence by paclitaxel in high-grade serous ovarian carcinoma (HGSOC) cells renders the cells resistant to paclitaxel but sensitizes them to BCL-xL targeting agents. Yang Yang. UTHSCSA, San Antonio, Texas, United States.